Grade 3 Anaplastic Ependymoma

An anaplastic ependymoma is a fast-growing brain or spinal cord tumor that comes from ependymal cells — the cells that line the fluid-filled spaces (ventricles) of the brain and the central canal of the spinal cord. “Anaplastic” means the tumor cells look very abnormal and tend to grow and divide more quickly than typical ependymoma cells. In older systems, anaplastic ependymoma was called WHO grade 3 ependymoma. Today, doctors still see tumors with “anaplastic” features, but the modern World Health Organization (WHO) system groups ependymomas mainly by where they start (supratentorial brain, posterior fossa brain, or spine) and by key molecular changes, because these predict behavior better than the old words alone. In practice, an “anaplastic” ependymoma is one of the higher-grade, more aggressive forms within those newer groups. PMC+2PMC+2

Anaplastic ependymoma is a fast-growing (grade 3) tumor that starts from ependymal cells—the cells lining the fluid-filled spaces of the brain and the central canal of the spinal cord. Doctors now often describe ependymomas using where they start (supratentorial, posterior fossa, or spinal) and their molecular features (for example, ZFTA-fusion or YAP1-fusion in the supratentorial region). Since the 2021 WHO CNS classification, “anaplastic ependymoma” is used less as a standalone name; instead, tumors in each location may be graded 2 or 3 based on aggressive features (many mitoses, microvascular proliferation, and necrosis). The word “anaplastic” still signals grade 3 (more aggressive) behavior. PMC+2jpatholtm.org+2

Ependymomas can occur at any age, but posterior fossa tumors (back of the brain) are more common in children, while spinal tumors are more common in adults. Symptoms depend on the tumor’s location and its pressure effects. Cancer.gov+1

---

Other names

• Anaplastic ependymoma (WHO grade 3) — older grading term still used in reports when cells look very abnormal and fast-growing.

• Ependymoma, CNS WHO grade 3 — same meaning as above, stated in the old grading style.

• Supratentorial ependymoma, ZFTA fusion–positive — a modern, gene-defined supratentorial type that often corresponds to aggressive behavior (many earlier “anaplastic” tumors here). National Brain Tumor Society+2AACR Journals+2

• Supratentorial ependymoma, YAP1 fusion–positive — another modern supratentorial type (usually in younger children). National Brain Tumor Society+1

• Posterior fossa ependymoma, group A (PFA) and group B (PFB) — modern posterior fossa types defined by DNA methylation; PFA is common in younger children and often behaves more aggressively. PMC+1

• Spinal ependymoma, MYCN-amplified — a newly recognized spinal type that tends to be aggressive and may show anaplastic features. PMC+1

Note: WHO 2021 emphasizes site + molecular type. “Anaplastic” is a microscopic description that can still appear, but the precise type above carries more prognostic weight. PMC

---

Types

Doctors now place ependymomas into groups based on location and molecular signature:

1. Supratentorial (upper brain)

   • ZFTA fusion–positive (formerly “RELA fusion”)

   • YAP1 fusion–positive
     These are defined by specific gene fusions. Many high-grade/anaplastic tumors in the cerebrum fall here. National Brain Tumor Society+1

2. Posterior fossa (back of the brain)

   • PFA (group A)

   • PFB (group B)
     These are defined by DNA methylation patterns; PFA usually affects younger children and often has a worse outlook than PFB. PMC+1

3. Spinal ependymomas

   • Conventional spinal ependymoma

   • Spinal ependymoma, MYCN-amplified (a newly recognized, aggressive subset that often has anaplastic features)

   • Myxopapillary ependymoma (re-graded to WHO grade 2 because it can recur and spread)

   • Subependymoma (usually low-grade) PMC+2jpatholtm.org+2

---

Causes and contributing factors

For ependymoma, no single everyday exposure has been proven to cause the disease. Instead, research points to genetic/molecular changes inside tumor cells and where the tumor arises in the brain or spine. Below are 20 evidence-based factors/associations explained in plain language:

1. Overall cause remains unknown
   Most cases have no clear outside trigger. The disease appears to start from transformation of ependymal lineage cells. PMC

2. ZFTA–RELA fusion (supratentorial)
   A gene fusion between ZFTA and RELA drives many supratentorial ependymomas and turns on growth programs; these tumors often behave aggressively. AACR Journals+1

3. YAP1 fusion (supratentorial)
   Another gene fusion that defines a different supratentorial type, often in younger children; behavior can differ from ZFTA-RELA tumors. ScienceDirect

4. PFA epigenetic pattern (posterior fossa)
   PFA tumors show a distinct methylation profile and often loss of the histone mark H3K27me3, linked to worse outcomes in children. ScienceDirect

5. PFB epigenetic pattern (posterior fossa)
   PFB tumors have a different methylation profile and generally a better outlook than PFA in older children/adolescents. PMC

6. MYCN amplification (spine)
   Extra copies of the MYCN gene define a new, aggressive spinal subtype prone to early spread and anaplastic features. PMC+1

7. Chromosome 1q gain
   Extra copies of the 1q region are common in some ependymomas and are tied to worse prognosis; this reflects underlying tumor biology. PMC+1

8. CDKN2A/B deletion
   Loss of these cell-cycle brake genes is linked with more aggressive disease and multiple recurrences in some series. ResearchGate

9. Chromosome 6q loss in PFA
   Deletion of 6q is reported as an additional poor prognostic factor in PFA tumors. Cancer.gov+1

10. NF2 pathway alterations (especially spine)
    Changes on chromosome 22q and the NF2 gene pathway are seen in spinal ependymomas and can contribute to tumor development. PMC

11. Male sex (epidemiologic association)
    Ependymoma is reported a bit more often in males, especially in certain locations; this is an association, not a proven cause. Cancer.gov

12. Age and site biology
    Young children are more likely to get posterior fossa tumors (often PFA), while adults more often get spinal tumors — this pattern reflects developmental biology of the nervous system. Cancer.gov

13. Developmental origin near ventricular surfaces
    Ependymomas arise from cells lining ventricles/central canal, which explains their typical locations and patterns of growth. Radiopaedia

14. Incomplete surgical removal (not a cause, but a driver of recurrence)
    When a tumor cannot be fully removed, the residual cells can regrow; this is a major prognostic factor across types. PMC

15. Telomerase activation in some subgroups
    Telomerase pathway activation has been associated with poorer outcome in specific groups like PFA, marking more aggressive biology. MDPI

16. EGFR over-expression (some intracranial cases)
    Over-active growth signaling (e.g., EGFR) has been noted in research cohorts and relates to more aggressive behavior. Frontiers

17. Prior cranial/spinal radiation (rare secondary tumors)
    Very rarely, brain or spine radiation for other conditions can be followed years later by secondary tumors, including ependymoma; this is uncommon but recognized. (General neuro-oncology principle.) NCBI

18. Tumor cell proliferation index (Ki-67)
    A higher Ki-67 labeling index signals faster cell division and correlates with worse outcomes; it reflects tumor biology rather than being an outside cause. ResearchGate

19. DNA methylation class (molecular identity)
    The exact methylation “fingerprint” places the tumor into PFA/PFB or other classes that predict behavior and risk. PMC

20. Location-specific microenvironment
    Tumors in confined spaces (e.g., posterior fossa) can cause earlier pressure symptoms and complications, which may make them seem more aggressive clinically. (Site-behavior relationship noted across sources.) Radiopaedia+1

---

Symptoms

Symptoms depend on where the tumor grows and whether it blocks cerebrospinal fluid (CSF) or compresses nerves. Here are common, plain-language symptoms:

1. Headache that is worse in the morning — due to raised pressure inside the skull. Mayo Clinic

2. Nausea and vomiting — also from pressure or hydrocephalus when CSF flow is blocked. Mayo Clinic

3. Balance problems and unsteady walking — common with posterior fossa tumors affecting the cerebellum. Cancer.gov

4. Neck stiffness or head tilt in children — from posterior fossa involvement and pressure. NCBI

5. Double vision or abnormal eye movements — pressure on brainstem/cranial nerves. NCBI

6. Seizures — more likely with supratentorial (cerebral) tumors. Mayo Clinic

7. Behavior or school-performance changes — frontal or temporal lobe effects. NCBI

8. Drowsiness or irritability — from raised intracranial pressure in young children. NCBI

9. Back pain (often midline) that may worsen with coughing/straining — with spinal ependymomas. NewYork-Presbyterian

10. Leg or arm weakness — spinal cord compression. NewYork-Presbyterian

11. Numbness/tingling or electric-shock sensations — nerve pathway irritation in the cord. NewYork-Presbyterian

12. Changes in bowel or bladder control — spinal cord/cauda equina involvement. NewYork-Presbyterian

13. Neck or shoulder pain with radiating symptoms — cervical cord tumors. Radiopaedia

14. Head-size increase or a bulging soft spot in infants — hydrocephalus from blocked CSF flow. NCBI

15. Sudden worsening (headache, vomiting, lethargy) — may signal acute hydrocephalus and needs urgent care. Cancer.gov

---

Diagnostic tests

A) Physical examination

1. General neurological exam
   The clinician checks strength, sensation, reflexes, coordination, and cranial nerve function to localize where the nervous system is affected. Abnormalities guide which imaging to order first. NCBI

2. Funduscopic (eye-exam) check for papilledema
   Looking at the optic discs can reveal swelling from raised intracranial pressure, a clue to a mass or blocked CSF. NCBI

3. Gait and posture assessment
   Observing walking, stance, and head tilt can reveal cerebellar or brainstem involvement (common in posterior fossa tumors). Cancer.gov

4. Spine inspection and palpation
   Midline tenderness or pain increased by Valsalva suggests spinal pathology that warrants MRI of the whole spine. NewYork-Presbyterian

5. Developmental/behavioral screen in children
   Subtle changes in milestones or school performance can be early signs of a brain tumor and prompt timely imaging. NCBI

B) Manual bedside tests

6. Romberg and tandem gait tests
   Simple balance tests detect cerebellar or proprioceptive problems often seen with posterior fossa disease. NCBI

7. Finger-to-nose and heel-to-shin
   Coordination testing that localizes cerebellar dysfunction. NCBI

8. Visual field confrontation test
   Quick bedside screen for field cuts when supratentorial tumors affect optic pathways. NCBI

9. Cranial nerve examination (eye movements, facial strength, swallowing)
   Helps detect brainstem compression and directs imaging to the posterior fossa. NCBI

C) Laboratory and pathological tests

10. Surgical biopsy or resection with histology
    Microscopic study confirms the diagnosis. “Anaplastic” features include very brisk cell division (mitoses), microvascular proliferation, and necrosis; today, histology is interpreted alongside molecular tests. PMC

11. Immunohistochemistry (IHC)
    Markers such as GFAP, EMA, and pattern of H3K27me3 loss (especially in PFA) support the diagnosis and subtype. L1CAM can suggest ZFTA-RELA tumors. ResearchGate+1

12. Molecular fusion testing
    Tests detect ZFTA–RELA or YAP1 fusions in supratentorial tumors, which define the entity and inform prognosis. AACR Journals+1

13. DNA methylation profiling
    A powerful test that assigns the tumor to PFA/PFB or other reference classes, improving diagnostic accuracy and risk grouping. PMC

14. Copy-number profiling (e.g., 1q gain, 6q loss, CDKN2A/B deletion)
    These changes help with risk assessment; 1q gain and 6q loss are poor markers in some groups. PMC+1

15. MYCN testing in spinal tumors
    Detecting MYCN amplification identifies a distinct, more aggressive spinal subtype that often needs intensive management. PMC+1

D) Electrodiagnostic tests

16. Electroencephalogram (EEG)
    Used when seizures are part of the presentation, to document seizure activity and guide anti-seizure treatment. (Adjunct to imaging; not diagnostic of tumor type.) NCBI

17. Evoked potentials (visual/brainstem)
    Sometimes used pre-op or intra-op to monitor pathways affected by the tumor (e.g., visual or hearing pathways) and reduce surgical risk. NCBI

E) Imaging tests

18. MRI of the brain with and without contrast (gadolinium)
    This is the main test for suspected brain ependymoma. It shows the mass, its relation to ventricles, signs of “drop” spread, and hydrocephalus. MRI patterns differ by site; anaplastic tumors may show more edema or restricted diffusion. Radiopaedia+1

19. MRI of the entire spine with contrast
    Because ependymoma cells can spread through CSF, guidelines recommend imaging the whole neuraxis (brain and entire spine), ideally before surgery to avoid confusing postoperative changes with spread. Cancer.gov

20. MRI characteristics specific to anaplastic ependymoma
    Studies describe differences between supratentorial and infratentorial anaplastic ependymomas (location inside vs. outside ventricles, cysts, diffusion patterns), helping radiologists refine the diagnosis. Frontiers

21. CT scan of the head
    Useful in emergencies to detect hydrocephalus or bleeding; MRI still gives better detail for tumor definition. PMC

22. MR spectroscopy / perfusion (advanced MRI)
    Optional tools that assess tumor metabolism and blood flow and may help distinguish tumor from treatment effects. Frontiers

23. Post-operative MRI within 24–48 hours
    Done to check how much tumor was removed and to establish a new baseline for follow-up. Cancer.gov

24. Surveillance MRI over time
    Regular scans monitor for recurrence or CSF “drop” metastases after treatment. Frequency depends on age, site, and subtype.

Non-pharmacological treatments (therapies & others)

Each item includes a short description, purpose, and mechanism in simple words. These are evidence-guided supportive/rehabilitative measures that work alongside surgery/radiation—not instead of them.

1. Neurosurgical planning with advanced imaging
   What/why: Detailed MRI of the brain and full spine guides a plan to remove as much tumor as is safely possible and to look for spread. Purpose: Maximize safe resection; reduce complications. Mechanism: Shows tumor borders, relationships to nerves/vessels, and any seeding along CSF pathways so the surgeon can choose the best approach. Cancer.gov

2. Intra-operative neuro-monitoring (IONM)
   What/why: During surgery, monitoring of nerve pathways (e.g., motor, sensory, cranial nerves) helps protect function. Purpose: Reduce paralysis, speech or swallowing problems. Mechanism: Real-time electrical signals warn surgeons before an injury becomes permanent. PMC

3. Early postoperative rehabilitation (PT/OT)
   What/why: Physical and occupational therapy start soon after surgery. Purpose: Restore strength, balance, coordination, and independence in daily activities. Mechanism: Repetitive, task-specific training drives neuroplasticity and prevents deconditioning. PMC

4. Speech and swallowing therapy
   What/why: Posterior fossa tumors can affect speech and swallowing. Purpose: Improve clear speech, safe swallowing, and nutrition. Mechanism: Targeted exercises retrain muscles and compensatory strategies reduce aspiration risk. PMC

5. Neuropsychological assessment & cognitive rehab
   What/why: Tumor and treatment can affect attention, memory, processing speed. Purpose: Identify deficits and train work-arounds. Mechanism: Structured tasks and memory strategies strengthen networks that support learning and daily function. PMC

6. Exercise oncology program
   What/why: Supervised, gentle aerobic and resistance activity. Purpose: Reduce fatigue, improve mood, preserve muscle, support heart health. Mechanism: Regular physical activity improves mitochondrial function, lowers inflammation, and boosts conditioning. American Cancer Society+1

7. Individualized nutrition care
   What/why: A registered dietitian helps maintain strength and weight during/after therapy. Purpose: Fewer treatment breaks and better recovery. Mechanism: Adequate protein/calories and symptom-based tips (e.g., small frequent meals) support healing and immune function. American Cancer Society+1

8. Mind-body skills (mindfulness, breathing, CBT-I)
   What/why: Stress, poor sleep, and anxiety are common. Purpose: Better sleep, mood, and coping. Mechanism: Mindfulness and CBT-I calm sympathetic arousal; good sleep supports cognitive recovery and immunity. ESMO

9. Vestibular and balance therapy
   What/why: Posterior fossa disease can cause dizziness and imbalance. Purpose: Reduce falls, improve confidence. Mechanism: Habituation and gaze-stabilization exercises retrain vestibular pathways. PMC

10. Palliative care early integration
    What/why: Symptom control (pain, nausea), emotional support, and planning alongside active treatment. Purpose: Better quality of life and sometimes better tolerance of therapy. Mechanism: Multidisciplinary care addresses symptoms proactively and aligns treatment with goals. ESMO

11. School/work reintegration programs
    What/why: Children need education plans; adults may need graded return to work. Purpose: Maintain learning and employment. Mechanism: Accommodations (rest breaks, extra time) and cognitive supports bridge recovery. PMC

12. Smoking/alcohol counseling (if relevant)
    What/why: Healthy behaviors matter for long-term wellness. Purpose: Lower complications and improve overall health. Mechanism: Reducing toxins lowers systemic inflammation and supports recovery. World Cancer Research Fund

13. Seizure safety education
    What/why: Some supratentorial tumors cause seizures. Purpose: Reduce injury risk and triggers; medication adherence. Mechanism: Practical steps (sleep hygiene, avoiding missed doses) reduce breakthrough events. Note: No prophylactic anti-seizure drugs if you’ve never had a seizure. PMC

14. Hydrocephalus management education
    What/why: Blocked CSF flow can cause headaches and vomiting. Purpose: Recognize red flags early. Mechanism: Knowing when to seek care can prevent emergency deterioration. Cancer.gov

15. Caregiver and social-work support
    What/why: Families need navigation for logistics, leave, and finances. Purpose: Reduce stress that can disrupt treatment. Mechanism: Practical support improves adherence and well-being. ESMO

---

Drug treatments

In ependymoma, surgery + radiation are the main anti-tumor therapies. Medicines are used for symptoms, support, and sometimes tumor control (mostly in trials, in infants, or at recurrence). Exact doses and schedules are individualized; numbers below reflect common protocol ranges and should only be used by oncology teams.

1. Dexamethasone (steroid)
   Why: Quickly reduces brain swelling and pressure symptoms.
   Class & mechanism: Glucocorticoid; tightens leaky tumor blood vessels and lowers inflammatory edema.
   Typical dosing/time: Short courses around surgery or radiation; taper as soon as possible to limit side-effects.
   Side-effects: High blood sugar, mood changes, infection risk, muscle loss. Evidence note: Guidelines suggest using the lowest effective dose in symptomatic patients only. JAMA Network+1

2. Levetiracetam (anti-seizure, if seizures occur)
   Why: Control seizures in supratentorial disease or post-operative seizures.
   Class & mechanism: Antiseizure medication that modulates synaptic vesicle protein SV2A.
   Typical dosing/time: Oral/IV, titrated to effect. No prophylaxis if seizure-naïve, per SNO-EANO guidance.
   Side-effects: Sleepiness, irritability; rarely mood changes. PMC

3. Ondansetron (anti-nausea)
   Why: Prevent nausea from anesthesia, opioids, or chemo.
   Class & mechanism: 5-HT3 antagonist blocks serotonin in gut/brainstem.
   Typical dosing/time: Before and after risky treatments.
   Side-effects: Constipation, headache. ESMO

4. Proton-pump inhibitor (e.g., omeprazole) during steroid use
   Why: Protect stomach if on moderate/high-dose steroids.
   Class & mechanism: Reduces acid secretion.
   Side-effects: Headache, diarrhea; long use may affect minerals. cns.org

5. Acetaminophen/appropriate analgesics
   Why: Post-op pain and headaches.
   Class & mechanism: Central COX inhibition; escalates as needed under supervision.
   Side-effects: Liver toxicity at high doses; monitor totals. ESMO

6. Cisplatin (recurrent/selected pediatric regimens)
   Why: Part of combination chemotherapy in infants or recurrence when RT isn’t possible or has failed.
   Class & mechanism: DNA crosslinker causing tumor cell death.
   Typical protocol use: Included in multi-agent pediatric regimens (with vincristine, etoposide, cyclophosphamide).
   Side-effects: Nausea, kidney and hearing toxicity; careful monitoring required. Evidence: Responses are inconsistent; chemo is not standard first-line in most patients. ClinicalTrials.gov+1

7. Carboplatin (selected settings)
   Why: Platinum alternative with different toxicity profile.
   Mechanism: DNA crosslinker.
   Use: In multi-drug pediatric protocols around surgery/RT.
   Side-effects: Bone-marrow suppression; less nephro/ototoxicity than cisplatin. Frontiers

8. Cyclophosphamide (selected protocols)
   Why: Component of combination regimens.
   Class & mechanism: Alkylating agent causing DNA damage.
   Side-effects: Low blood counts, nausea; rare bladder toxicity (prevented with hydration/mesna). ClinicalTrials.gov

9. Ifosfamide (occasionally at relapse)
   Class & mechanism: Alkylating agent similar to cyclophosphamide.
   Side-effects: Encephalopathy risk, kidney toxicity; requires close monitoring. ResearchGate

10. Vincristine (combo regimens)
    Class & mechanism: Microtubule inhibitor that stops cell division.
    Side-effects: Neuropathy, constipation. ClinicalTrials.gov

11. Etoposide
    Class & mechanism: Topoisomerase II inhibitor causing DNA breaks.
    Side-effects: Low white cells, fatigue. ClinicalTrials.gov

12. Temozolomide (adults, off-label/relapse; limited activity)
    Class & mechanism: Oral alkylating agent (methylator).
    Evidence: Common in gliomas, but limited benefit in ependymoma; sometimes tried at recurrence.
    Side-effects: Cytopenias, fatigue, nausea. PMC

13. Bevacizumab (relapse, experimental/selected cases)
    Class & mechanism: Anti-VEGF monoclonal antibody; reduces blood vessel growth and edema.
    Evidence: Combo with lapatinib was tolerated but showed no objective responses in a pediatric trial.
    Side-effects: Hypertension, bleeding risk, proteinuria. PMC

14. Lapatinib (ERBB-targeted; investigational in ependymoma)
    Class & mechanism: ERBB1/2 tyrosine-kinase inhibitor.
    Evidence: Phase II with bevacizumab did not show tumor shrinkage in children.
    Side-effects: Diarrhea, rash. PMC

15. Checkpoint inhibitors (e.g., nivolumab/pembrolizumab) (clinical trials)
    Class & mechanism: PD-1 inhibitors release immune brakes.
    Evidence: Only isolated case stability; overall benefit in ependymoma remains unproven outside trials.
    Side-effects: Immune-related inflammation (thyroid, skin, gut). PubMed+1

16. Antiemetic backbone (e.g., aprepitant when high-emetogenic chemo is used)
    Mechanism: NK1-receptor blockade complements 5-HT3 antagonists + dexamethasone.
    Purpose: Prevent severe nausea/vomiting with platinums. ESMO

17. Growth-factor support (e.g., filgrastim) with myelosuppressive chemo
    Mechanism: G-CSF stimulates neutrophil recovery to reduce infection risk.
    Note: Supportive care, not tumor therapy. ESMO

18. Pain medicines step-wise (NSAIDs/weak–strong opioids as needed)
    Purpose: Control pain to maintain function and nutrition.
    Mechanism: Peripheral and central analgesia pathways; careful, individualized use. ESMO

19. Thromboprophylaxis (case-by-case)
    Why: Brain tumor and immobility raise clot risk; balance with bleeding risk.
    Mechanism: Anticoagulants reduce clot formation where appropriate. ESMO

20. Antibiotic prophylaxis only when indicated (e.g., post-op or prolonged neutropenia)
    Purpose: Prevent infection in high-risk periods.
    Mechanism: Target likely organisms; time-limited use. ESMO

---

Dietary molecular supplements

These can help with nutrition symptoms and general health when coordinated with the oncology team. They do not treat the tumor. Doses below reflect common safe ranges; your clinicians will tailor them.

1. Medical nutrition shakes (protein-calorie formulas)
   What they do: Provide concentrated calories and protein when appetite is poor.
   Dose: As advised by the dietitian to meet daily targets.
   Function/mechanism: Maintain weight and lean mass; easier to sip than full meals. American Cancer Society

2. Whey or plant protein powder
   Dose: Often 20–30 g per serving to reach daily protein goals.
   Function: Supports muscle repair and immune proteins.
   Mechanism: Supplies essential amino acids for recovery. PMC

3. Omega-3 fatty acids (EPA/DHA)
   Dose: Commonly 1–2 g/day combined EPA+DHA (check interactions).
   Function: May help with cancer-related weight loss and inflammation.
   Mechanism: Anti-inflammatory lipid mediators; support appetite and muscle metabolism. PMC

4. Vitamin D (if deficient)
   Dose: Individualized to labs; often 800–2000 IU/day maintenance.
   Function: Bone/muscle health during steroids/less mobility.
   Mechanism: Corrects deficiency; supports neuromuscular function. PMC

5. Multivitamin at RDA levels
   Dose: Once daily.
   Function: Back-up for poor intake; avoid mega-doses.
   Mechanism: Provides baseline micronutrients without pharmacologic doses. World Cancer Research Fund

6. Fiber supplements (psyllium/inulin) as needed
   Dose: Start low (e.g., 3–5 g/day) with fluids.
   Function: Helps constipation from opioids/vincristine; stabilizes stool.
   Mechanism: Adds bulk and prebiotic activity. American Cancer Society

7. Electrolyte solutions
   Dose: As needed during vomiting/diarrhea.
   Function: Replace fluids and salts.
   Mechanism: Glucose-sodium co-transport improves absorption. American Cancer Society

8. Probiotics (case-by-case)
   Dose: Product-specific; avoid during severe neutropenia.
   Function: May reduce antibiotic-associated diarrhea.
   Mechanism: Supports gut microbiome balance. ESPEN

9. Ginger (dietary or standardized capsules)
   Dose: 0.5–1 g/day divided (if approved).
   Function: Helps nausea in some patients.
   Mechanism: Antiemetic effects in GI tract and CNS. American Cancer Society

10. Calcium (only if diet is low and D is optimized)
    Dose: Typically to reach ~1000–1200 mg/day total from diet + supplement.
    Function: Bone health with steroids and less activity.
    Mechanism: Mineral support for bone remodeling. PMC

Important: Major organizations (WCRF/AICR) advise not using high-dose supplements to prevent or treat cancer; focus on food first unless your team recommends otherwise. World Cancer Research Fund

---

Immunity-booster / regenerative / stem-cell drugs

There are no approved “regenerative” or “stem-cell drugs” that treat anaplastic ependymoma. However, a few supportive or investigational therapies are relevant:

1. Filgrastim (G-CSF) — supportive only. Speeds white-blood-cell recovery during chemo to lower infection risk; does not treat the tumor. ESMO

2. Erythropoiesis-stimulating agents (select cases) — Treat chemo-related anemia under strict criteria; risks and benefits are weighed carefully. ESMO

3. Checkpoint inhibitors (e.g., nivolumab/pembrolizumab) — Investigational in ependymoma; occasional stable disease reported, but benefit remains unproven outside trials. PubMed

4. HER2-targeted CAR-T cells — Clinical trials are ongoing in recurrent/progressive pediatric ependymoma; still experimental. ClinicalTrials+1

5. Bevacizumab — Reduces VEGF-mediated edema; sometimes used at relapse to control symptoms, but pediatric trial with lapatinib showed no objective responses. PMC

6. Everolimus/other targeted agents — Studied in select brain tumors; limited data in ependymoma. Consider trial enrollment when appropriate. PMC

---

Key surgeries

1. Maximal safe resection (first surgery)
   Procedure: Craniotomy (brain) or laminectomy/laminoplasty (spine) to remove all visible tumor without harming critical structures.
   Why: Gross total resection is the strongest predictor of better outcomes. PubMed+1

2. Second-look resection
   Procedure: Planned or delayed re-operation if early MRI shows residual tumor and a safer route is possible.
   Why: Increases chance of complete removal before radiotherapy. PMC

3. Endoscopic-assisted intraventricular tumor removal (select cases)
   Procedure: Minimally invasive tools for tumors inside ventricles.
   Why: Reduce brain retraction, blood loss, and hospital stay when anatomy allows. PMC

4. CSF diversion (external drain or shunt) for hydrocephalus
   Procedure: Temporary drain or permanent shunt if CSF is blocked.
   Why: Relieves pressure and prevents life-threatening deterioration. Cancer.gov

5. Re-resection at recurrence (case-by-case)
   Procedure: Surgical removal of regrowth when safely feasible.
   Why: Can extend survival even at second recurrence in carefully selected patients. The Journal of Neurosurgery

---

Prevention tips

There is no proven way to prevent ependymoma. These tips focus on overall cancer risk reduction and resilience during/after treatment:

1. Don’t smoke or vape; avoid second-hand smoke. World Cancer Research Fund

2. Keep a healthy weight over time. World Cancer Research Fund

3. Be physically active most days; sit less. World Cancer Research Fund

4. Eat a plant-forward pattern (vegetables, fruits, whole grains, legumes). American Cancer Society+1

5. Limit ultra-processed foods and added sugars. World Cancer Research Fund

6. Limit red and processed meats. World Cancer Research Fund

7. If you drink alcohol, limit or avoid it. World Cancer Research Fund

8. Keep up with vaccinations and routine medical care. ESMO

9. Seek dietitian input early if weight is falling or appetite is poor. American Cancer Society

10. Consider clinical trials at diagnosis or recurrence—they may offer access to better therapies. Cancer.gov

---

When to see a doctor urgently

• Worsening headache, repeated vomiting, new drowsiness, or vision changes.

• New seizure, severe neck stiffness, or sudden weakness/numbness.

• Signs of hydrocephalus (severe morning headache, vomiting, gait problems).

• After treatment: new neurological symptoms or rapid symptom change at any time. Cancer.gov

---

What to eat (and what to avoid)

What to eat: small, frequent meals; high-protein choices (eggs, yogurt, beans, chicken, fish), whole grains, colorful vegetables, fruits, nuts, and healthy fats; sip oral nutrition drinks if full meals are hard. Why: Keeps strength up, supports healing, and may reduce infection risk. American Cancer Society+1

What to avoid/limit: alcohol; very spicy/greasy foods if they worsen nausea; high-sugar drinks; large, heavy meals before radiation; mega-dose supplements unless your team prescribes them. Focus on food first, not pills. World Cancer Research Fund

---

Frequently asked questions (FAQ)

1) Is “anaplastic ependymoma” still the official name?
Today, doctors emphasize location + molecular type and then grade (2 or 3). “Anaplastic” still means grade 3 but the label appears less often by itself. PMC+1

2) What’s the most important treatment step?
A maximal safe resection by an experienced neurosurgical team, followed by focused radiotherapy. PMC+1

3) Is proton therapy better than photon therapy?
For children, proton therapy often reduces radiation to healthy tissues with similar tumor control; dosimetry and outcome studies support its use when available. Oxford Academic+2PMC+2

4) Does chemotherapy cure ependymoma?
No. Chemo has limited benefit and is usually used in trials, in infants to delay RT, or at recurrence. PMC

5) What are typical radiation doses?
A common pediatric dose after surgery is 59.4 Gy (older than 18 months) to the tumor bed with a margin; younger children receive less. Cancer.gov

6) Will I need anti-seizure medication?
Only if you’ve had a seizure. Preventive antiseizure drugs are not recommended for seizure-naïve patients with brain tumors. PMC

7) Can diet or supplements treat the tumor?
No. Food and supplements support strength and recovery but do not shrink ependymoma. Avoid high-dose supplements unless prescribed. World Cancer Research Fund

8) Are there promising new treatments?
Trials are testing immunotherapies (e.g., CAR-T targeting HER2/B7-H3) and other targeted drugs, but none is standard yet. ClinicalTrials+1

9) What if the tumor returns?
Doctors may consider re-resection, re-irradiation (sometimes proton), and clinical trials; outcomes vary by location and prior treatments. The Journal of Neurosurgery+1

10) How often will I need scans?
Follow-up MRIs of the brain (and spine when indicated) happen regularly for years; timing is individualized. Medscape

11) Does complete removal always cure it?
Not always, but complete resection plus radiation gives the best chance of long control. PubMed

12) Can ependymoma spread through the CSF?
Yes, it can “seed” the spinal canal; that is why staging MRI of the entire spine (and CSF cytology when safe) is recommended. Cancer.gov

13) Are children and adults treated the same?
Principles overlap, but age, location, and molecular type influence choices (e.g., proton therapy in children; spinal tumors more common in adults). Cancer.gov+1

14) What side-effects should I expect from radiation?
Fatigue, skin irritation, hair loss in the treated area; long-term risks depend on dose/volume and are usually lower with proton therapy in children. Oxford Academic

15) Where can I find authoritative, clinician-updated summaries?
NCI’s PDQ pages (childhood ependymoma), EANO and NCCN guidance summaries, and recent reviews are reliable places to start.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 16, 2025.